Coagulation and fibrinolytic disturbances in women with polycystic ovary syndrome

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 4, 2011, Pages 1068-1076

  Manneras Holm, Louise ^a   Baghaei, Fariba ^b   Holm, Göran ^c   Janson, Per Olof ^a   Ohlsson, Claes ^d   Lönn, Malin ^a   Stener Victorin, Elisabet ^a,e  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b Institute of Medicine   (Sweden)

^c Metabolism and Cardiovascular Research   (Sweden)

^d Institute of Medicine   (Sweden)

^e HEILONGJIANG UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8; C REACTIVE PROTEIN; D DIMER; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; FIBRINOGEN; INSULIN; TISSUE PLASMINOGEN ACTIVATOR; VON WILLEBRAND FACTOR;

ADULT; ANTHROPOMETRY; ARTICLE; BLOOD CLOTTING; BLOOD PRESSURE; BODY MASS; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; ENZYME ACTIVITY; FEMALE; FIBRINOLYSIS; HEART RATE; HEMODYNAMICS; HEMOSTASIS; HUMAN; INSULIN SENSITIVITY; LINEAR REGRESSION ANALYSIS; LIPID ANALYSIS; MAJOR CLINICAL STUDY; OUTCOME ASSESSMENT; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY ANALYSIS; SYSTOLIC BLOOD PRESSURE;

ADULT; BIOLOGICAL MARKERS; BLOOD COAGULATION; BLOOD COAGULATION DISORDERS; BODY MASS INDEX; CASE-CONTROL STUDIES; FEMALE; FIBRINOLYSIS; GONADAL STEROID HORMONES; HEMODYNAMICS; HUMANS; LIPIDS; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYCYSTIC OVARY SYNDROME; REGRESSION ANALYSIS; YOUNG ADULT;

EID: 79953877335     PISSN: 0021972X     EISSN: 0021972X     Source Type: Journal    
DOI: 10.1210/jc.2010-2279     Document Type: Article

References (37)

1. The Rotterdam ESHRE/ASRM Sponsored PCOS Consensus Workshop Group 2004 Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 19:41-47
2. Teede HJ, Hutchison S, Zoungas S, MeyerC2006 Insulin resistance, the metabolic syndrome, diabetes, and cardiovascular disease risk in women with PCOS. Endocrine 30:45-53 (Pubitemid 46020329)
3. Lo JC, Feigenbaum SL, Yang J, Pressman AR, Selby JV, Go AS 2006 Epidemiology and adverse cardiovascular risk profile of diagnosed polycystic ovary syndrome. J Clin Endocrinol Metab 91:1357-1363
4. Moran LJ, Hutchison SK, Meyer C, Zoungas S, Teede HJ 2009 A comprehensive assessment of endothelial function in overweight women with and without polycystic ovary syndrome. Clin Sci (Lond) 116:761-770
5. Tarkun I, Cantürk Z, Arslan BC, Türemen E, Tarkun P 2004 The plasminogen activator system in young and lean women with polycystic ovary syndrome. Endocr J 51:467-472 (Pubitemid 39536354)
6. Dahlgren E, Janson PO, Johansson S, Lapidus L, Lindstedt G, Tengborn L 1994 Hemostatic and metabolic variables in women with polycystic ovary syndrome. Fertil Steril 61:455-460 (Pubitemid 24083145)
7. Kelly CJ, Lyall H, Petrie JR, Gould GW, Connell JM, Rumley A, Lowe GD, Sattar N 2002 A specific elevation in tissue plasminogen activator antigen inwomenwith polycystic ovarian syndrome. J Clin Endocrinol Metab 87:3287-3290 (Pubitemid 34816378)
8. Kebapcilar L, Taner CE, Kebapcilar AG, Sari I 2009 High mean platelet volume, low-grade systemic coagulation and fibrinolytic activation are associated with androgen and insulin levels in polycystic ovary syndrome. Arch Gynecol Obstet 280:187-193
9. Carmassi F, De Negri F, Fioriti R, De Giorgi A, Giannarelli C, Fruzzetti F, Pedrinelli R, Dell'Omo G, Bersi C 2005 Insulin resistance causes impaired vasodilation and hypofibrinolysis in young women with polycystic ovary syndrome. Thromb Res 116:207-214 (Pubitemid 40776019)
10. Yildiz BO, Haznedarodlu IC, Kirazli S, Bayraktar M 2002 Global fibrinolytic capacity is decreased in polycystic ovary syndrome, suggesting a prothrombotic state. J Clin Endocrinol Metab 87:3871-3875 (Pubitemid 34879542)
11. Lindholm A, Bixo M, Eliasson M, Hudecova M, Arnadottir R, Holte J, Poromaa IS 2010 Tissue plasminogen activator and plasminogen activator inhibitor 1 in obese and lean patients with polycystic ovary syndrome. Gynecol Endocrinol 26:743-748
12. Erdodan M, Karadeniz M, Alper GE, Tamsel S, Uluer H, Cadlayan O, Saygili F, Yilmaz C 2008 Thrombin-activatable fibrinolysis inhibitor and cardiovascular risk factors in polycystic ovary syndrome. Exp Clin Endocrinol Diabetes 116:143-147 (Pubitemid 351518531)
13. Atiomo WU, Fox R, Condon JE, Shaw S, Friend J, Prentice AG, Wilkin TJ 2000 Raised plasminogen activator inhibitor-1 (PAI-1) is not an independent risk factor in the polycystic ovary syndrome (PCOS). Clin Endocrinol (Oxf) 52:487-492 (Pubitemid 30249817)
14. Rajendran S, Willoughby SR, Chan WP, Liberts EA, Heresztyn T, Saha M, Marber MS, Norman RJ, Horowitz JD 2009 Polycystic ovary syndrome is associated with severe platelet and endothelial dysfunction in both obese and lean subjects. Atherosclerosis 204: 509-514
15. Schuring AN, Schulte N, Sonntag B, Kiesel L 2008 Androgens and insulin: Two key players in polycystic ovary syndrome. Gynäkol Geburtshilfliche Rundsch 48:9-15
16. Friedewald WT, Levy RI, Fredrickson DS 1972 Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem 18:499-502
17. Stener-Victorin E,HolmG, Labrie F, Nilsson L, Janson PO, Ohlsson C 2010 Are there any sensitive and specific sex steroid markers for polycystic ovary syndrome? J Clin Endocrinol Metab 95:810-819
18. Mannerås-Holm L, Leonhardt H, Kullberg J, Jennische E, Oden A, Holm G, Hellström M, Lönn L, Olivecrona G, Stener-Victorin E, LönnM17 November 2010 Adipose tissue has aberrant morphology and function in PCOS: Enlarged adipocytes and low serum adiponectin, but not circulating sex steroids, are strongly associated with insulin resistance. J Clin Endocrinol Metab 10.1210/jc.2010- 1290
19. Björnheden T, Jakubowicz B, Levin M, Odén B, Edén S, Sjöström L, Lönn M 2004 Computerized determination of adipocyte size. Obes Res 12:95-105 (Pubitemid 41137492)
20. Goldrick RB 1967 Morphological changes in the adipocyte during fat deposition and mobilization. Am J Physiol 212:777-782
21. Sverrisdóttir YB, Mogren T, Kataoka J, Janson PO, Stener-Victorin E 2008 Is polycystic ovary syndrome associated with high sympathetic nerve activity and size at birth? Am J Physiol Endocrinol Metab 294:E576-E581 (Pubitemid 351355228)
22. Mertens I, Van Gaal LF 2002 Obesity, haemostasis and the fibrinolytic system. Obes Rev 3:85-101 (Pubitemid 34827150)
23. KannelWB1997 Influence of fibrinogen on cardiovascular disease. Drugs 54:32-40 (Pubitemid 27488853)
24. Danesh J, Collins R, Appleby P, Peto R 1998 Association of fibrinogen, C-reactive protein, albumin, or leukocyte count with coronary heart disease: Meta-analyses of prospective studies. JAMA 279: 1477-1482 (Pubitemid 28228207)
25. Diamanti-Kandarakis E, Paterakis T, Kandarakis HA 2006 Indices of low-grade inflammation in polycystic ovary syndrome. Ann NY Acad Sci 1092:175-186 (Pubitemid 47092336)
26. Pai JK, Pischon T, Ma J, Manson JE, Hankinson SE, Joshipura K, Curhan GC, Rifai N, Cannuscio CC, Stampfer MJ, Rimm EB 2004 Inflammatory markers and the risk of coronary heart disease in men and women. N Engl J Med 351:2599-2610 (Pubitemid 39628581)
27. Haverkate F 2002 Levels of haemostatic factors, arteriosclerosis and cardiovascular disease. Vascul Pharmacol 39:109-112 (Pubitemid 36398232)
28. Kelly CC, Lyall H, Petrie JR, GouldGW,Connell JM, SattarN2001 Low grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 86:2453-2455 (Pubitemid 32545690)
29. Olufadi R, Byrne CD 2006 Effects of VLDL and remnant particles on platelets. Pathophysiol Haemost Thromb 35:281-291 (Pubitemid 44155946)
30. Mineo C, Deguchi H, Griffin JH, Shaul PW 2006 Endothelial and antithrombotic actions of HDL. Circ Res 98:1352-1364 (Pubitemid 43948059)
31. Diamanti-Kandarakis E, Papavassiliou AG, Kandarakis SA, Chrousos GP 2007 Pathophysiology and types of dyslipidemia in PCOS. Trends Endocrinol Metab 18:280-285 (Pubitemid 47332216)
32. Stegenga ME, Van Der Crabben SN, Levi M, de Vos AF, TanckMW, Sauerwein HP, Van Der Poll T 2006 Hyperglycemia stimulates coagulation, whereas hyperinsulinemia impairs fibrinolysis in healthy humans. Diabetes 55:1807-1812 (Pubitemid 44324136)
33. Schneider DJ, Sobel BE 1996 Synergistic augmentation of expression of plasminogen activator inhibitor type-1 induced by insulin, very-low-density lipoproteins, and fatty acids. Coron Artery Dis 7:813-817 (Pubitemid 27020353)
34. Devin JK, Johnson JE, Eren M, Gleaves LA, Bradham WS, Bloodworth Jr JR, Vaughan DE 2007 Transgenic overexpression of plasminogen activator inhibitor-1 promotes the development of polycystic ovarian changes in female mice. J Mol Endocrinol 39:9-16 (Pubitemid 47337862)
35. Raynaud E, Pérez-Martin A, Brun J, Aíssa-Benhaddad A, Fédou C, Mercier J 2000 Relationships between fibrinogen and insulin resistance. Atherosclerosis 150:365-370 (Pubitemid 30336548)
36. Blombäck M, Konkle BA, Manco-Johnson MJ, Bremme K, Hellgren M, Kaaja R 2007 Preanalytical conditions that affect coagulation testing, including hormonal status and therapy. J Thromb Haemost 5:855-858 (Pubitemid 46563587)
37. Siegbahn A, Odlind V, Hedner U, Venge P 1989 Coagulation and fibrinolysis during the normal menstrual cycle. Ups J Med Sci 94: 137-152 (Pubitemid 19159903)